Dr Reddy’s Lab Q3 Results Preview: Pharma firm expected to clock sluggish December quarter results

Dr Reddy’s Lab Q3 Results Preview: One of India's top pharmaceutical firms, Dr Reddy’s Lab, is expected to have a sluggish quarter as the company is set to report its December-quarter results on Tuesday (January 30, 2024). 

Zee Business research estimates the pharma firm to report a five per cent jump in its consolidated profit after tax (PAT) to Rs 1310 crore in the December quarter against Rs 1247 crore in the same quarter last fiscal.

Research says price erosion and a decline in Revlimid medicine contribution are set to impact the company's consolidated revenue from operations. 

Street expects a jump of just two per cent in the pharma firm's revenue to Rs 6914 crore in the quarter under review against Rs 6770 crore a year ago.

Dr Reddy’s Lab's earnings before interest, taxes, depreciation and amortization (EBITDA), which is a key measure of profitability, is expected to be flat at Rs 1967 crore against 1966 crore Year-on-Year (YoY).

Analysts' estimate the company's margins for the December quarter to be 28 per cent, which will be lower than 29 per cent the firm clocked in the same quarter last fiscal.

Other factors to watch out for in Q3 results

Dr Reddy’s income from the United States is expected to grow by 4 four per cent. 

Research estimates the company to see 6-7 per cent growth in its domestic business.

The company's focus will be on filings, approvals, and launches, research says.

A weakness is expected in the cardiac therapy business of the company.